根据社会人口结构层次的第四阶段NSCLC的最近生存率增长
Oluwaseun F Ayoade1, Maureen E Canavan2, Emily J Zolfaghari1
1Division of Thoracic Surgery, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut.
JTO clinical and research reports
|April 11, 2025
概括
最近的创新已经改善了第四阶段非小细胞肺癌 (NSCLC) 患者的生存率. 然而,在各个社会人口统计学群体中,生存率的增长有很大差异,这突显了治疗结果的差异.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 流行病学 流行病学
背景情况:
- 第四阶段非小细胞肺癌 (NSCLC) 的治疗已经被最近的治疗进展彻底改变了.
- 跨社会人口群体获得这些医疗创新的差异可能会影响结果的改善.
- 评估不同人群中IV期NSCLC患者的现实生存率的增长至关重要.
研究的目的:
- 评估IV期NSCLC患者最近的实际生存率的改善情况.
- 分析美国各个社会人口统计学群体的生存率增长.
- 为了确定治疗结果的潜在差异.
主要方法:
- 利用国家癌症数据库分析从2010年到2020年被诊断为IV期NSCLC的治疗患者.
- 数据分为三个不同的治疗时期:2010-2013,2014-2017和2018-2020.
- 通过Kaplan-Meier方法评估两年生存率,并通过分层Cox分析分析调整的死亡风险.
主要成果:
- 总共包括了393,586名患者. 免疫治疗的使用率显著增加,从2.0%增加到51.8%,而化疗和放射治疗的使用率有所下降.
- 在第一个和最后一个时代之间,总体中位数的生存率增加了53.7% (6.7到10.3个月).
- 根据种族/种族和保险状况,生存率的增加有所不同,西班牙裔患者和私人保险患者的增加更大.
结论:
- 在过去十年中,治疗IV期NSCLC患者的存活率明显改善.
- 在社会人口统计学群体之间观察到生存增长和改善速度的显著差异.
- 需要进一步的研究来了解结果的变化,并提高NSCLC治疗的公平性和有效性.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
990
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
185
相关概念视频
Cancer Survival Analysis
308
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308
Comparing the Survival Analysis of Two or More Groups
92
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
92
Actuarial Approach
49
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
49
Assumptions of Survival Analysis
71
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
71
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Kaplan-Meier Approach
60
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
60
